Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor

Journal of Acquired Immune Deficiency Syndromes

Volumn 27, Issue 5, 2001, Pages 443-449

  Rakotoambinina, Benjamin ^a,b   Médioni, Jacques ^a   Rabian, Cécile ^a   Jubault, Vincent ^a   Jais, Jean Philippe ^a   Viard, Jean Paul ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b Faculty of Medicine   (Madagascar)

Author keywords

HIV infection; Hyperlipidemia; Lipodystrophy; Nucleoside analogs; Protease inhibitors

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CHOLESTEROL; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TRIACYLGLYCEROL; ZALCITABINE; ZIDOVUDINE;

ADULT; AGE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; COHORT ANALYSIS; DRUG EXPOSURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INCIDENCE; LIPOATROPHY; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL STATUS; PRIORITY JOURNAL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

EID: 0035881189     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200108150-00004     Document Type: Article

References (32)

1. Indinavir-associated lipodystrophy
2. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
3. Development of cervical fat pads following therapy with human immunodeficiency virus type 1 inhibitors
4. "Buffalo hump" in men with HIV-1 infection
5. Visceral abdominal-fat accumulation associated with the use of indinavir
6. Diagnosis, prediction and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
7. Severe premature coronary heart disease with protease inhibitors
8. Vascular complications associated with use of HIV protease inhibitors
9. Vascular complications associated with use of HIV protease inhibitors
10. Vascular complications associated with use of HIV protease inhibitors
11. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired glucose tolerance in HIV-1-infected patients
12. Protease inhibitor-associated hyperinsulinemia
13. Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors
14. Hyperlipidaemia following treatment with protease inhibitors in patients with HIV infection
15. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART)
16. Insulin resistance in HIV protease inhibitor-associated diabetes
17. Lipodystrophy may be a consequence of prolonged survival
18. Metabolic abnormalities and use of HIV-1 protease inhibitors
19. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
20. Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis
21. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving longterm nucleoside analogue therapy
22. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy
23. A syndrome of lipodystrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
24. Mitochondrial toxicity induced by nucleoside analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
25. Ingrown toenails and indinavir: Case-control study demonstrates strong relationship
26. The role of the cytokines, interferon alpha and tumor necrosis factor in the hypertriglyceridemia and wasting of AIDS
27. Inflammatory cytokines and inhibitors in HIV infection: Correlation between interleukin-1 antagonist and weight loss
28. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
29. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: Correlation between dyslipidemia and steroid hormone alterations
30. Alteration of tumor necrosis factor-α T-cell homeostasis following potent antiretroviral therapy: Contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome
31. Syndromes of severe insulin resistance
32. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection